Meghan Delaney Appointed CEO of New York Blood Center Enterprises
New York Blood Center Enterprises (NYBCe) has appointed Meghan Delaney, DO, MPH, as its next President and Chief Executive Officer. She will assume the role starting January 4, 2027.
New York Blood Center Enterprises (NYBCe) announced that its Board of Trustees has appointed Meghan Delaney, DO, MPH, as the organization's next President and Chief Executive Officer. Dr. Delaney will officially take on the leadership position on January 4, 2027, succeeding Christopher D. Hillyer, MD.
Dr. Hillyer, who has led NYBCe since 2009, will transition to serve as a Special Advisor to the Board of Trustees. During his 17-year tenure, he oversaw the expansion of NYBCe from a regional blood center into a life sciences enterprise serving 16 states and over 550 hospitals. Under his leadership, the organization advanced its capabilities in genomics, cellular therapies, and biomanufacturing, including achieving FDA approval for the hematopoietic progenitor cell therapy product HemaCord.
Dr. Delaney currently holds executive positions at Children's National in Washington, D.C., including Associate Chief Clinical Officer and Chief of Pathology and Laboratory Medicine. She also serves as a Professor at the George Washington University School of Medicine and Health Sciences and is on the Board of Directors for the Association for the Advancement of Blood & Biotherapies (AABB).
Founded in 1964, NYBCe is one of the largest nonprofit blood centers in the United States, delivering over one million blood products annually to nearly 550 hospitals. The organization is also involved in research related to hematology and transfusion medicine.